Anthony Donaghue, Author at Born2Invest

Anthony Donaghue

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.

Born2Invest uses cookies in order to improve your experience and make further customizations to how we present our content. By continuing to use our website, you accept and give your consent to our practices as described in the following: our revised Privacy Policy, Cookie Policy, and Terms of Use.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Born2Invest

Anthony Donaghue

Stories By Anthony Donaghue

Peaches Biotech Receives €2M from the Government for Advanced Therapy Projects

Iñaki Berenguer Adds Valencian Investors to LifeX Ventures Biotech Fund

Biontaxis Receives €1.1 Million from the Government for Research in Gene Therapies

The Spanish Pharmaceutical Sector Closes Q1 with a 10.5% Drop on the Stock Market

Vytrus Biotech Increases Sales by 31% and Achieves an EBITDA of €1.5 Million

Moderna Will Pay $70 Million to Generation Bio for Genetic Medicines

AstraZeneca Increases Its Commitment to Spain with More Investments

Nowture Launches Two New Health Companies with an Investment of Four Million

Nexkin Medical Advances in Allergology and Prepares its Commercial Jump to Europe

Reig Jofre Increases Profit by 62% in 2022, Up to €8.1 Million